JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 245 products of "JAK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 490
CAS:Formula:C17H14N2O3Purity:>98.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:294.31Ilginatinib hydrochloride
CAS:<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formula:C21H21ClFN7Purity:99.55%Color and Shape:SolidMolecular weight:425.89TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Formula:C28H32N4O3SPurity:99.02% - 99.59%Color and Shape:SolidMolecular weight:504.64N-(3-Aminopropyl)cyclohexylamine
CAS:<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Formula:C9H20N2Purity:98.05% - 98.82%Color and Shape:Pale Yellow Clear LiquidMolecular weight:156.2685Brepocitinib P-Tosylate
CAS:<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Formula:C25H29F2N7O4SPurity:99.82% - 99.97%Color and Shape:SolidMolecular weight:561.6WDR5-IN-6
CAS:<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Formula:C13H8Cl2N2O2SPurity:99.69%Color and Shape:SoildMolecular weight:327.19Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Formula:C24H28N8O2Purity:98.06% - 99.94%Color and Shape:SolidMolecular weight:460.53(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS:Formula:C17H14N2O3Purity:98%Color and Shape:SolidMolecular weight:294.3047Ilginatinib
CAS:<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formula:C21H20FN7Purity:98.4% - 99.01%Color and Shape:SolidMolecular weight:389.43JAK2 Inhibitor V
CAS:<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Formula:C23H24N2OPurity:98.36% - 99.15%Color and Shape:SolidMolecular weight:344.45Golidocitinib
CAS:<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Formula:C25H31N9O2Purity:98.87% - 99.88%Color and Shape:SolidMolecular weight:489.57Ilginatinib maleate
CAS:<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formula:C25H24FN7O4Purity:99.74% - 99.82%Color and Shape:SolidMolecular weight:505.5Delgocitinib
CAS:<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Formula:C16H18N6OPurity:99.95%Color and Shape:SolidMolecular weight:310.35Nimucitinib
CAS:<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Formula:C25H26F2N6O2Purity:98.71%Color and Shape:SoildMolecular weight:480.51HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Formula:C60H69N17O11SColor and Shape:SolidMolecular weight:1236.36JAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Formula:C33H33D3FN9O2Color and Shape:SolidMolecular weight:612.71DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formula:C25H38N4O3Color and Shape:SolidMolecular weight:442.59Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Formula:C17H18N6Color and Shape:SolidMolecular weight:314.41MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formula:C23H26N4O2SColor and Shape:SolidMolecular weight:422.54FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Color and Shape:LiquidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Color and Shape:Odour SolidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Color and Shape:Odour SolidJAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Color and Shape:Odour SolidTyk2-IN-22
CAS:<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Formula:C16H16ClN5O2Color and Shape:SolidMolecular weight:345.78JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Color and Shape:Odour SolidJAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formula:C18H20F3N7OColor and Shape:SolidMolecular weight:407.401JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formula:C22H23FN4O3SColor and Shape:SolidMolecular weight:442.51S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Formula:C17H18N6Purity:98%Color and Shape:SolidMolecular weight:306.37TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formula:C23H21FN4O2Color and Shape:SolidMolecular weight:404.16485JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formula:C30H33FN4O3SColor and Shape:SolidMolecular weight:548.67Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formula:C63H107N19O20S2Purity:98%Color and Shape:SolidMolecular weight:1514.77SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Formula:C43H45N13O9SPurity:98%Color and Shape:SolidMolecular weight:919.96JAK2-IN-6
CAS:<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Formula:C14H10ClN3OS2Purity:99.64%Color and Shape:SolidMolecular weight:335.83SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formula:C36H36N10O5Color and Shape:SolidMolecular weight:688.74WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formula:C29H31F3N4O4Color and Shape:SolidMolecular weight:556.576SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Formula:C41H46N12O5SColor and Shape:SolidMolecular weight:818.95Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Formula:C17H20N8O2SPurity:99.94%Color and Shape:SoildMolecular weight:400.46SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formula:C42H43N13O7SColor and Shape:SolidMolecular weight:873.94TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Color and Shape:Odour SolidPROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formula:C55H69N13O7SPurity:98%Color and Shape:SolidMolecular weight:1056.28AS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Formula:C18H19N5OColor and Shape:SolidMolecular weight:321.38JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Formula:C17H14ClN5O2Purity:98%Color and Shape:SolidMolecular weight:355.78JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Purity:98%Color and Shape:Odour SolidLH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Formula:C29H31F3N6O2SColor and Shape:SolidMolecular weight:584.66JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Formula:C30H32N8O5SColor and Shape:SolidMolecular weight:616.69JI069
CAS:<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Formula:C15H12Cl2N2O4SPurity:98.01%Color and Shape:SolidMolecular weight:387.24Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Formula:C88H138N20O34P2Purity:98%Color and Shape:SolidMolecular weight:2082.1Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Formula:C23H25F5N7O5PPurity:99.57%Color and Shape:SolidMolecular weight:605.45JAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Formula:C20H12ClN3OColor and Shape:SolidMolecular weight:345.79WHI-P180 Hydrochloride
CAS:Formula:C16H15N3O3·HClPurity:>97.0%(T)(HPLC)Color and Shape:White to Light gray to Light yellow powder to crystalMolecular weight:333.77DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Formula:C26H35N7O5Color and Shape:SolidMolecular weight:525.6Atinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Formula:C16H17FN6O3Purity:99.36%Color and Shape:SolidMolecular weight:360.35Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Formula:C32H33F4N9O5Color and Shape:SolidMolecular weight:699.66Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Formula:C20H18FN5O3Purity:98.05%Color and Shape:SolidMolecular weight:395.39WHI-P154
CAS:Formula:C16H14BrN3O3Purity:>98.0%(HPLC)Color and Shape:White to Yellow to Orange powder to crystalMolecular weight:376.21CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Formula:C22H19F2N5O2Purity:99.38%Color and Shape:SolidMolecular weight:423.42Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Formula:C17H17N7O2SPurity:99.88%Color and Shape:SolidMolecular weight:383.43PF-06651600 malonate
CAS:<p>PF-06651600 is a potent and selective JAK3 inhibitor.</p>Formula:C18H23N5O5Color and Shape:SolidMolecular weight:389.41Pacritinib
CAS:<p>Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).</p>Formula:C28H32N4O3Purity:99.25% - 99.49%Color and Shape:SolidMolecular weight:472.58Filgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Formula:C21H23N5O3SPurity:98.03% - ≥95%Color and Shape:SolidMolecular weight:425.5Baricitinib phosphate
CAS:<p>Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.</p>Formula:C16H20N7O6PSPurity:99.4% - 99.82%Color and Shape:SolidMolecular weight:469.41WDR5-0103 hydrochloride[890190-22-4(free base)]
<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>Formula:C21H26ClN3O4Purity:99.66%Color and Shape:SolidMolecular weight:419.9Solcitinib
CAS:<p>Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.</p>Formula:C22H23N5O2Purity:99.61% - 99.82%Color and Shape:SolidMolecular weight:389.45Fosifidancitinib
CAS:<p>Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.</p>Formula:C21H21FN5O7PPurity:99.54%Color and Shape:SolidMolecular weight:505.39JAK3-IN-6
CAS:<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Formula:C19H18N4O3Purity:99.94% - 99.94%Color and Shape:SolidMolecular weight:350.37WHI-P97 HCl
<p>WHI-P97 HCl is a potent and selective JAK-3 inhibitor.</p>Formula:C16H14Br2ClN3O3Purity:99.49%Color and Shape:SolidMolecular weight:491.56SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formula:C18H22N8O2SPurity:99.11%Color and Shape:SolidMolecular weight:414.48Gusacitinib HCl
CAS:<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Formula:C24H29ClN8O2Color and Shape:SolidMolecular weight:497Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Formula:C15H19N5OPurity:98.82% - 99.92%Color and Shape:SolidMolecular weight:285.34GLPG0634 analog
CAS:<p>GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.</p>Formula:C23H18N6O2Purity:99.52% - >99.99%Color and Shape:SolidMolecular weight:410.43Ruxolitinib
CAS:<p>Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.</p>Formula:C17H18N6Purity:99.4% - >99.99%Color and Shape:SolidMolecular weight:306.36Tofacitinib
CAS:<p>Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.</p>Formula:C16H20N6OPurity:99% - >99.99%Color and Shape:SolidMolecular weight:312.37Itacitinib
CAS:<p>Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.</p>Formula:C26H23F4N9OPurity:96.4% - 99.5%Color and Shape:SolidMolecular weight:553.51(Z)-LFM-A13
CAS:<p>(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.</p>Formula:C11H8Br2N2O2Purity:99.88%Color and Shape:SolidMolecular weight:360Fedratinib
CAS:<p>Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.</p>Formula:C27H36N6O3SPurity:97.31% - 99.96%Color and Shape:SolidMolecular weight:524.68Ritlecitinib tosylate
CAS:<p>Ritlecitinib (PF-06651600) is a potent, selective JAK3 inhibitor with proven in vivo efficacy, low clearance, and has undergone clinical trials.</p>Formula:C22H27N5O4SColor and Shape:SolidMolecular weight:457.549Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Formula:C17H18N6Purity:99.37% - 99.79%Color and Shape:SolidMolecular weight:306.36WHI-P154
CAS:<p>WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.</p>Formula:C16H14BrN3O3Purity:98% - 99.67%Color and Shape:SolidMolecular weight:376.2Momelotinib
CAS:<p>Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.</p>Formula:C23H22N6O2Purity:97.47% - 99.56%Color and Shape:SolidMolecular weight:414.46Ruxolitinib phosphate
CAS:<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Formula:C17H21N6O4PPurity:98% - >99.99%Color and Shape:SolidMolecular weight:404.36BD750
CAS:<p>BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in</p>Formula:C14H13N3OSPurity:99.02%Color and Shape:SolidMolecular weight:271.34Abrocitinib
CAS:<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Formula:C14H21N5O2SPurity:99.09% - 99.91%Color and Shape:SolidMolecular weight:323.41Atractylenolide I
CAS:<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Formula:C15H18O2Purity:97.55% - 99.92%Color and Shape:SolidMolecular weight:230.3NVP-BSK805 trihydrochloride
CAS:<p>NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.</p>Formula:C27H31Cl3F2N6OColor and Shape:SolidMolecular weight:599.93Upadacitinib
CAS:<p>Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.</p>Formula:C17H19F3N6OPurity:98.96% - 99.94%Color and Shape:SolidMolecular weight:380.37AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formula:C19H23N7O2Purity:99.83% - 99.98%Color and Shape:SolidMolecular weight:381.43Pacritinib hydrochloride
CAS:<p>Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.</p>Formula:C28H32N4O3·xClHColor and Shape:SolidRGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Formula:C29H35N7O4Purity:98% - 99.91%Color and Shape:SolidMolecular weight:545.63Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Formula:C23H25ClFN7OPurity:99.33% - 99.86%Color and Shape:SolidMolecular weight:469.94Oclacitinib
CAS:<p>Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000</p>Formula:C15H23N5O2SPurity:98% - 98.45%Color and Shape:White To Off-White SolidMolecular weight:337.44Cucurbitacin I
CAS:<p>Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.</p>Formula:C30H42O7Purity:96.69% - 99.8%Color and Shape:SolidMolecular weight:514.65Oclacitinib maleate
CAS:<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Formula:C15H23N5O2S·C4H4O4Purity:99.17%Color and Shape:SolidMolecular weight:453.51CEP-33779
CAS:<p>CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.</p>Formula:C24H26N6O2SPurity:98.24% - ≥95%Color and Shape:SolidMolecular weight:462.57Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Formula:C23H24Cl2N6O2Color and Shape:SolidMolecular weight:487.38Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Formula:C22H28N6O8Purity:99.19% - 99.75%Color and Shape:SolidMolecular weight:504.49JAK-IN-5 hydrochloride
CAS:<p>JAK-IN-5 hydrochloride is a JAK inhibitor [1].</p>Formula:C27H32ClFN6OColor and Shape:SolidMolecular weight:511.03AZD-1480
CAS:<p>AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.</p>Formula:C14H14ClFN8Purity:98.25% - 99.47%Color and Shape:SolidMolecular weight:348.77RO8191
CAS:<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Formula:C14H5F6N5OPurity:98% - 98.85%Color and Shape:SolidMolecular weight:373.21Curculigoside
CAS:<p>1.</p>Formula:C22H26O11Purity:99.85%Color and Shape:SolidMolecular weight:466.44XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formula:C25H28N6O2Purity:99.19%Color and Shape:SolidMolecular weight:444.532,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Formula:C16H13Cl2N3O2Purity:98.77%Color and Shape:SolidMolecular weight:350.2Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Formula:C20H27N7O3SPurity:98.74% - 99.49%Color and Shape:SolidMolecular weight:445.54Protosappanin A
CAS:<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Formula:C15H12O5Purity:99.42% - 99.82%Color and Shape:SolidMolecular weight:272.25AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Formula:C29H28F3N5O2Purity:98%Color and Shape:SolidMolecular weight:535.56Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Formula:C18H19F3N6OPurity:99.28% - >99.99%Color and Shape:SolidMolecular weight:392.38G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Formula:C22H19F2NO3Purity:97.3%Color and Shape:SolidMolecular weight:383.39(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Formula:C23H24N4OPurity:97.75% - 99.92%Color and Shape:SolidMolecular weight:372.46FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formula:C28H32O6Purity:97% - 97.90%Color and Shape:SolidMolecular weight:464.55AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formula:C17H14N2O3Purity:98.6% - 99.39%Color and Shape:Yellow SolidMolecular weight:294.3GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Formula:C28H28ClF2N9O3Purity:99.75%Color and Shape:SolidMolecular weight:612.03Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Formula:C16H17N7O2SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:371.42Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Formula:C18H22N4O2Purity:98.67% - 99.4%Color and Shape:SolidMolecular weight:326.39Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Formula:C18H16FN3OPurity:97.1% - 98.74%Color and Shape:SolidMolecular weight:309.34WHI-P97
CAS:<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Formula:C16H13Br2N3O3Purity:99.93%Color and Shape:SolidMolecular weight:455.1JANEX-1
CAS:<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Formula:C16H15N3O3Purity:98% - 99.81%Color and Shape:SolidMolecular weight:297.31WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Formula:C17H14BrN3OPurity:98.92% - 99.73%Color and Shape:SolidMolecular weight:356.22Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Formula:C27H40Cl2N6O4SPurity:98.96% - 99.87%Color and Shape:SolidMolecular weight:615.61AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Formula:C18H16F2N6Purity:96.02% - 98.51%Color and Shape:SolidMolecular weight:354.36ZM39923 hydrochloride
CAS:<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Formula:C23H25NO·HClPurity:98.05%Color and Shape:SolidMolecular weight:367.91BMS-911543
CAS:<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Formula:C23H28N8OPurity:97.69% - 99.98%Color and Shape:SolidMolecular weight:432.52SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Formula:C21H18ClFN4O4Purity:98.99% - 99.77%Color and Shape:SolidMolecular weight:444.84FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Formula:C24H24N6O2Purity:98.44%Color and Shape:SolidMolecular weight:428.49TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Formula:C26H35N7O2SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:509.67Deucravacitinib
CAS:<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Formula:C20H19D3N8O3Purity:98.52% - >99.99%Color and Shape:SolidMolecular weight:425.46RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Formula:C17H14Cl2N6OPurity:97.94%Color and Shape:SolidMolecular weight:389.24SC99
CAS:<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Formula:C15H8Cl2FN3OPurity:99.56%Color and Shape:SolidMolecular weight:336.15Brevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Formula:C20H26O5Purity:99.97% - >99.99%Color and Shape:SolidMolecular weight:346.42Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Formula:C20H28ClN7O3SPurity:99.85%Color and Shape:SolidMolecular weight:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Formula:C17H19N5O2SPurity:99.93%Color and Shape:SolidMolecular weight:357.43NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Formula:C27H28F2N6OPurity:98%Color and Shape:SolidMolecular weight:490.55Solrikitug
CAS:<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Purity:95%Color and Shape:LiquidZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Formula:C23H25NOPurity:98%Color and Shape:SolidMolecular weight:331.45(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37SD-1029
CAS:<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Formula:C25H32Br2Cl2N2O3Color and Shape:SolidMolecular weight:639.25JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Formula:C23H22FN5O4SPurity:99.75%Color and Shape:SolidMolecular weight:483.52JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Formula:C28H30FN7O2Color and Shape:SolidMolecular weight:515.58JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Formula:C19H19ClN2OSColor and Shape:SolidMolecular weight:358.89Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Formula:C18H23ClN4O2Color and Shape:SolidMolecular weight:362.86TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Formula:C21H22N2O2Color and Shape:SolidMolecular weight:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Formula:C19H19N3O4SColor and Shape:SolidMolecular weight:385.44JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Formula:C19H15FN4OPurity:98.27%Color and Shape:SolidMolecular weight:334.35TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Formula:C16H18N6OPurity:98%Color and Shape:SolidMolecular weight:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Formula:C27H28F2N6O3Color and Shape:SolidMolecular weight:522.55JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Formula:C19H19N5O4SColor and Shape:SolidMolecular weight:413.45Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Formula:C21H19FN8O2Purity:98%Color and Shape:SolidMolecular weight:434.43EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Formula:C14H24O2Color and Shape:SolidMolecular weight:224.34Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Formula:C18H15D3N6O3SPurity:98%Color and Shape:SolidMolecular weight:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Formula:C21H18N2O3Purity:98%Color and Shape:SolidMolecular weight:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Formula:C6H6Br6Purity:98%Color and Shape:SolidMolecular weight:557.54OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Formula:C28H29F3N4O4Purity:98%Color and Shape:SolidMolecular weight:542.55INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Formula:C19H11Cl2N5Color and Shape:SolidMolecular weight:380.23JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Formula:C17H23N5O4SColor and Shape:SolidMolecular weight:393.46TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Formula:C22H25F2N5O2Color and Shape:SolidMolecular weight:429.46CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formula:C21H18ClF2N7O3Color and Shape:SolidMolecular weight:489.86Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Formula:C18H23BrN4O2Color and Shape:SolidMolecular weight:407.312Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Formula:C23H22F5N7OColor and Shape:SolidMolecular weight:507.469(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Formula:C15H19N5OColor and Shape:SolidMolecular weight:285.34TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Formula:C28H28ClN5O4SColor and Shape:SolidMolecular weight:566.07PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Formula:C18H26N6OColor and Shape:SolidMolecular weight:342.44SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Formula:C24H26N8O3Color and Shape:SolidMolecular weight:474.52JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Formula:C26H30ClN7O2Color and Shape:SolidMolecular weight:508.02JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Formula:C20H18FN5O3SPurity:99.53%Color and Shape:SolidMolecular weight:427.45JAK-IN-28
CAS:<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Formula:C20H18ClN7OPurity:98%Color and Shape:SolidMolecular weight:407.86JAK-IN-30
CAS:<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Formula:C19H26N8SPurity:98%Color and Shape:SolidMolecular weight:398.53JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Formula:C26H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Formula:C25H32N8O2Purity:99.64% - 99.87%Color and Shape:SolidMolecular weight:476.57Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Formula:C22H28N6O2Purity:99.72%Color and Shape:SolidMolecular weight:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Formula:C18H15FN4O3Purity:98.61% - 99.81%Color and Shape:SolidMolecular weight:354.34Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Formula:C12H12N4O5Color and Shape:SolidMolecular weight:292.25JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Formula:C25H28N8OPurity:97.89%Color and Shape:SolidMolecular weight:456.54Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Formula:C22H26N8Purity:99.82%Color and Shape:SolidMolecular weight:402.50STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Formula:C15H15ClN4O2Purity:99.01%Color and Shape:SolidMolecular weight:318.76JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Formula:C22H23FN4O3SPurity:98.4%Color and Shape:SolidMolecular weight:442.51JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Formula:C21H21N5O2Purity:99.59%Color and Shape:SolidMolecular weight:375.42Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Formula:C29H32Cl2N2O5SPurity:99.51% - 99.83%Color and Shape:SoildMolecular weight:591.55JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formula:C19H17N5O4Purity:98%Color and Shape:SolidMolecular weight:379.37Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formula:C33H38F2N6O8Color and Shape:SolidMolecular weight:684.69TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formula:C27H25F3N4O4Purity:99.39% - ≥98%Color and Shape:SolidMolecular weight:526.51Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Formula:C17H19F2N7OSPurity:98%Color and Shape:SolidMolecular weight:407.44JAK-IN-5
CAS:<p>JAK-IN-5 is a JAK inhibitor.</p>Formula:C27H31FN6OPurity:98.1% - 99.37%Color and Shape:SolidMolecular weight:474.57JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purity:98%Color and Shape:SolidMolecular weight:442.523JAK2-IN-4
CAS:<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>Formula:C23H27N5O4SPurity:98%Color and Shape:SolidMolecular weight:469.56TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Formula:C18H21F2N7OPurity:99.82%Color and Shape:SolidMolecular weight:389.4ABBV-712
CAS:<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Formula:C24H28N4O5Purity:98%Color and Shape:SolidMolecular weight:452.5Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formula:C26H29ClN8OColor and Shape:SolidMolecular weight:505.01Ginsenoside Rk1
CAS:<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Formula:C42H70O12Purity:98.46% - 99.13%Color and Shape:SolidMolecular weight:767JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46QL-1200186
CAS:<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Formula:C26H27N7O3Purity:98%Color and Shape:SolidMolecular weight:485.54
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
